Colchicine as A Potential Therapy in Hepatocellular Carcinoma: A Review

Gembong Satria Mahardhika, Azizah Nurul Ilmi, I Gede Arinton, Suharno Suharno

Abstract


Background:  Liver cancer is the seventh most common cancer and the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is a challenging disease to treat and has a poor prognosis. Colchicine is an old drug that was recently found to have anticancer activities towards several cancer cells. This article aimed to review the potential properties of colchicine as chemotherapy for HCC.

Methods: The literature review was done by searching databases from PubMed, Cochrane, and ProQuest from June 4th to 26th, 2021. Full-text articles were searched by literature search strategies. The articles were screened by abstract and title. Studies that met the criteria were screened for full text.

Results: Forty-six articles were identified, seven articles were screened for titles and abstracts, and three articles were excluded owing to full-text unavailability. Four articles were reviewed.

Conclusions: The potential of colchicine as a preventive therapy in HCC needs to be further explored, and additional tests need to be done, especially in vivo. Larger population studies should also be done to evaluate the safety, usefulness, and feasibility of colchicine, especially in HCC.


Keywords


anticancer agent, liver cancer, preventive therapy, colchicine

References


Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

Petrick JL, McGlynn KA. The changing epidemiology

of primary liver cancer. Curr Epidemiol reports. 2019;6(2):104.

Raza A, Sood GK. Hepatocellular carcinoma review:

Current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115.

Wu S, Wang Y, Sun L, et al. Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer. 2011;11(1):413.

Lin ZY, Kuo CH, Wu DC, Chuang WL. Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J Med Sci. 2016;32(2):68–73.

Lin ZY, Wu CC, Chuang YH, Chuang WL. Anti-cancer

mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci. 2013 Sep 3;93(8):323–8.

McLoughlin EC, O’Boyle NM. Colchicine-Binding Site

Inhibitors from Chemistry to Clinic: A Review. Pharm. 2020;13(1):8.

Krinsky G, Shanbhogue K. Proliferative versus Nonproliferative Hepatocellular Carcinoma: Clinical

and Imaging Implications. Radiology. 2021;300(3):583–5.

Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–30.

Lin ZY, Yeh ML, Huang CI, et al. Potential of novel

colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. Kaohsiung J Med Sci. 2021;37(7):616–23.

EASL Clinical Practice Guidelines: Management of

hepatocellular carcinoma. J Hepatol. 2018;69(1):182–

Dudkiewicz I, Brosh T, Perelman M, Salai M. Colchicine inhibits fracture union and reduces bone strength—in vivo study. J Orthop Res. 2005;23(4):877–81.

Bhattacharya S, Das A, Datta S, et al. Colchicine induces autophagy and senescence in lung cancer cells at clinically admissible concentration: potential use of colchicine in combination with autophagy inhibitor in cancer therapy. Tumor Biol. 2016;37(8):10653–64.

Lu Y, Chen J, Xiao M, et al. An overview of tubulin inhibitors that interact with the colchicine binding

site. Pharm Res. 2012;29(11):2943–71.

Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs

That Target Dynamic Microtubules: A New Molecular

Perspective. Med Res Rev. 2011;31(3):443.

Sivakumar G. Colchicine Semisynthetics: Chemotherapeutics for Cancer? Curr Med Chem.

Feb 18;20(7):892–8.

Cocco G, Chu DCC, Pandolfi S. Colchicine in clinical

medicine. A guide for internists. Eur J Intern Med.

;21(6):503–8.

Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine

poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48(5):407–14.

Imazio M, Bobbio M, Cecchi E, et al. Colchicine in

Addition to Conventional Therapy for Acute Pericarditis. Circulation. 2005;112(13):2012–6.

Imazio M, Brucato A, Trinchero R, et al. Colchicine

for pericarditis: hype or hope? Eur Heart J. 2009;30(5):532–9.

Kallinich T, Haffner D, Niehues T, et al. Colchicine

Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and C o n s e n s u s S t a t e m e n t . P e d i a t r i c s . 2007;119(2):e474–83.

Rubin CI, Atweh GF. The role of stathmin in the

regulation of the cell cycle. J Cell Biochem. 2004;93(2):242–50.

Maldonado EN, Patnaik J, Mullins MR, Lemasters

JJ. Free Tubulin Modulates Mitochondrial Membrane

Potential in Cancer Cells. Cancer Res. 2010;70(24):10192.

Zhang T, Chen W, Jiang X, et al. Anticancer effects

and underlying mechanism of Colchicine on human

gastric cancer cell lines in vitro and in vivo. Biosci Rep. 2019;39(1).

Liu CY, Liao HF, Shih SC, et al. Colchicine sensitizes

human hepatocellular carcinoma cells to damages

caused by radiation. World J Gastroenterol. 2005;11(27):4237.

Shen J, Zhang Y, Yu H, et al. Role of DUSP1/MKP1

in tumorigenesis, tumor progression and therapy.

Cancer Med. 2016;5(8):2061.

Fakih M, Replogle T, Lehr JE,. Inhibition of prostate

cancer growth by estramustine and colchicine.Prostate. 1995;26(6):310–5.

Maryam A, Mehmood T, Yan Q, et al. Proscillaridin

A Promotes Oxidative Stress and ER Stress, Inhibits

STAT3 Activation, and Induces Apoptosis in A549

Lung Adenocarcinoma Cells. Oxid Med Cell Longev.

;2018.

Zhu X, Li Z, Li T, et al. Osthole inhibits the PI3K/

AKT signaling pathway via activation of PTEN and

induces cell cycle arrest and apoptosis in esophageal

squamous cell carcinoma. Biomed Pharmacother.

;102:502–9.

Sarveazad A, Agah S, Babahajian A, et al. Predictors

of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci. 2019;(1).

Kuo MC, Chang SJ, Hsieh MC. Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: Awww.indonesianjournalofcancer.or.id

P-ISSN: 1978-3744 E-ISSN: 2355-6811

|

Lin ZY, Yeh ML, Huang CI, et al. Potential of novel

colchicine dosage schedule for the palliative

treatment of advanced hepatocellular carcinoma.

Kaohsiung J Med Sci. 2021;37(7):616–23.

Wells RG, Kruglov E, Dranoff JA. Autocrine release

of TGF-β by portal fibroblasts regulates cell growth. FEBS Lett. 2004;559(1–3):107–10.

Sun CK, Chua MS, He J, So SK. Suppression of

Glypican 3 Inhibits Growth of Hepatocellular Carcinoma Cells through Up-Regulation of TGF-β2. Neoplasia. 2011;13(8):735.

Hayashi M, Nomoto S, Kanda M, et al. Identification

of the a kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma. J Surg Oncol. 2012;105(4):381–6.

Akakura S, Gelman IH. Pivotal Role of AKAP12 in

the Regulation of Cellular Adhesion Dynamics: Control of Cytoskeletal Architecture, Cell Migration, and Mitogenic Signaling. J Signal Transduct. 2012;2012:1–7.

Liu W, Guan M, Hu T, et al. Re-Expression of AKAP12

Inhibits Progression and Metastasis Potential of Colorectal Carcinoma In Vivo and In Vitro. PLoS One. 2011;6(8):e24015.

Tao T, Ji Y, Cheng C, et al. Tumor necrosis factoralpha inhibits Schwann cell proliferation by upregulating Src-suppressed protein kinase C substrate expression. J Neurochem. 2009;111(3):647–55.

Numajiri A, Mibayashi M, Nagata DK. StimulusDependent and Domain-Dependent Cell Death

Acceleration by an IFN-Inducible Protein, Human MxA. J Interferon Cytokine Res. 2006;26(4):214–9.

Haruki AN, Naito T, Nishie T, Saito S, Nagata K. Interferon-Inducible Antiviral Protein MxA Enhances Cell Death Triggered by Endoplasmic Reticulum Stress.

J Interferon Cytokine Res. 2011;31(11):847–56.

Mushinski JF, Nguyen P, Stevens LM, et al. Inhibition

of Tumor Cell Motility by the Interferon-inducible GTPase MxA. J Biol Chem. 2009 May 29;284(22):15206.

Kask L, Trouw LA, Dahlbäck B, Blom AM. The C4bbinding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells. J Biol Chem. 2004;279(23):23869–73.

Trouw LA, Nilsson SC, Gonçalves I, et al. C4b-binding

protein binds to necrotic cells and DNA, limiting

DNA release and inhibiting complement activation.

J Exp Med. 2005;201(12):1937.

Moghadaszadeh B, Beggs AH. Selenoproteins and

Their Impact on Human Health Through Diverse

Physiological Pathways. Physiology (Bethesda). 2006;21(5):307.

Patterson KI, Brummer T, O’Brien PM, Daly RJ. Dualspecificity phosphatases: critical regulators with diverse cellular targets. Biochem J. 2009;418(3):475–89.

Seternes OM, Kidger AM, Keyse SM. Dual-specificity

MAP kinase phosphatases in health and disease. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):124.

Kidger AM, Keyse SM. The regulation of oncogenic

Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs). Semin Cell Dev Biol. 2016;50:125.

Chen K, Gorgen A, Ding A, et al. Dual-Specificity

Phosphatase 9 Regulates Cellular Proliferation and

Predicts Recurrence After Surgery in Hepatocellular

Carcinoma. Hepatol Commun. 2021;5(7):1310.

Sizemore G, Pitarresi J, Balakrishnan S, et al. The

ETS family of oncogenic transcription factors in solid

tumours. Nat Rev Cancer. 2017;17(6):337–51. 50. Si Y, Liu X, Cheng M, et al. Growth Differentiation Factor 15 Is Induced by Hepatitis C Virus Infection and Regulates Hepatocellular Carcinoma-Related Genes. PLoS One. 2011;6(5):19967.

Sakai T, Balasubramanian K, Maiti S, et al. PlasminCleaved β-2-Glycoprotein 1 Is an Inhibitor of Angiogenesis. Am J Pathol. 2007;171(5):1659.

Davis MW, Wason S. Effect of steady-state atorvastatin on the pharmacokinetics of a single

dose of colchicine in healthy adults under fasted

conditions. Clin Drug Investig. 2014;34(4):259–67.

Frydrychowicz C, Pasieka B, Pierer M, et al. Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report. J Med Case Rep. 2017;11(1):1–5. 54. Oh DHJ, Chan SQ, Wilson AM. Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. Med J Aust. 2012;197(6):332–3.

Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicineinduced acute myopathy in a patient with

concomitant use of simvastatin. Clin Neuropharmacol.

;25(5):266–8.

Torgovnick J, Sethi N, Arsura E. Colchicine and HMG

Co-A reductase inhibitors induced myopathy-a case report. Neurotoxicology. 2006;27(6):1126–7.

Tufan A, Sener Dede D, Cavus S, et al. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40(7–8):1466–9.

Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30(6):799–802. 59. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94(9):1140–6. 12-Year Cohort Study. Medicine (Baltimore). 2015;94(50).


Full Text: PDF

DOI: 10.33371/ijoc.v16i2.844

Article Metrics

Abstract view : 77 times
PDF - 42 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.